myNEO says it has identified peptides (pieces of protein) that can trigger a highly targeted immune response. “By specifically choosing the fragments which are necessary for the functioning of the virus, the vaccine has a better effect against SARSCoV-2 (the virus responsible for Covid-19) and all other (future) forms of the same family of viruses containing these same parts“underlines Ghent biotech in a press release.
myNEO will now start pre-clinical trials. The objective is to carry out the first human vaccine tests in early 2021. It will be a vaccine targeting all common forms of Covid-19 as well as other viruses of the corona group such as SARS and MERS, aims for the start-up.